Immuno-Oncology and Technology : Impact Factor & More
eISSN: 2590-0188
Open AccessShare this on:
Key Metrics
CiteScore 
3
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Immuno-Oncology and Technology Journal Specifications
Indexed in the following public directories
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | Elsevier |
| Language | English |
| Article Processing Charges | EUR 2750 |
| Publication Time | 29 |
| Editorial Review Process | Double blind peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | European Society for Medical Oncology |
| Website URL | Visit website |
| Publication Details | |
| Publication Time | 29 |
| Waiver Policy | Visit website |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in Immuno-Oncology and Technology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Immuno-Oncology and Technology
Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer
- 6 Jun 2026
- Immuno-Oncology and Technology
Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures.
- 1 Jun 2026
- Immuno-oncology technology
The genome takes the wheel: CAR T with built-in circuits
- 8 May 2026
- Immuno-Oncology and Technology
Combining circulating inflammatory proteins and thymidine kinase activity to predict survival in melanoma patients receiving immune checkpoint inhibitors
- 19 Mar 2026
- Immuno-Oncology and Technology
Redirecting engineered immune cells using G protein-coupled receptors in cancer therapy.
- 1 Mar 2026
- Immuno-oncology technology
Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis.
- 1 Mar 2026
- Immuno-oncology technology
Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer
- 6 Jun 2026
- Immuno-Oncology and Technology
Fresh-blood immune profiling of immune-related adverse events in real-world patients identifies organ-specific and steroid responsiveness signatures.
- 1 Jun 2026
- Immuno-oncology technology
The genome takes the wheel: CAR T with built-in circuits
- 8 May 2026
- Immuno-Oncology and Technology
Combining circulating inflammatory proteins and thymidine kinase activity to predict survival in melanoma patients receiving immune checkpoint inhibitors
- 19 Mar 2026
- Immuno-Oncology and Technology
Redirecting engineered immune cells using G protein-coupled receptors in cancer therapy.
- 1 Mar 2026
- Immuno-oncology technology
Safety and efficacy of immune checkpoint inhibitors in patients with melanoma and pre-existing autoimmune conditions: a systematic review and meta-analysis.
- 1 Mar 2026
- Immuno-oncology technology
FAQs on Immuno-Oncology and Technology
How many articles did Immuno-Oncology and Technology publish last year? 
What is Citescore for Immuno-Oncology and Technology?
Who is the publisher of Immuno-Oncology and Technology?
